Page 269 - Haematologica Vol. 109 - July 2024

LETTER TO THE EDITOR
Biotherapeutics, Genmab, MorphoSys/Incyte and Vincerx. CST discloses research funding from Janssen, AbbVie and BeiGene; honoraria from Janssen, AbbVie, BeiGene, Loxo and AstraZeneca. LQ discloses consultancy for and speakers bureau of Janssen, AstraZeneca, Takeda, Roche, AbbVie and BeiGene. TS discloses employment at BeiGene Switzerland GmbH; is an equity holder of BeiGene Ltd. MZ, JP, LW, JZ and HM disclose employment at BeiGene. AC discloses employment at BeiGene; is an equity holder of BeiGene; discloses travel, accommodations, expenses from BeiGene. AT discloses consultancy for BeiGene, AstraZeneca, AbbVie and Janssen; honoraria from BeiGene, AstraZeneca, AbbVie and Janssen; speakers bureau of BeiGene, AstraZeneca, AbbVie and Janssen; travel, accommodations, expenses from BeiGene, AstraZeneca, AbbVie and Janssen.
Contributions
JRB, PG, WJ, BSK, NL, TR, MS, CST, LQ, and AT enrolled patients, performed research, and contributed to data collection, analysis, and interpretation. JP, TS, LW, MZ, AC, and HM contributed to this study’s conceptualization and design, data curation, formal analysis, data interpretation, methodology, and validation. All authors contributed to the writing, review, editing, and final approval of this manuscript.
Acknowledgments
The authors thank the patients and their families, investigators, co-investigators, and the study teams at each of the participating
References
1. Tam CS, Dimopoulos M, Garcia-Sanz R, et al. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv. 2022;6(4):1296-1308.
2. Hillmen P, Eichhorst B, Brown JR, et al. Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial. J Clin Oncol. 2023;41(5):1035-1045.
3. Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388(4):319-332.
4. Tam CS, Garcia-Sanz R, Opat S, et al. ASPEN: long-term follow- up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia. J Clin Oncol. 2022;40(s16):7521.
5. Tam CS, Opat S, D’Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038-2050.
6. Honda F, Kano H, Kanegane H, et al. The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils. Nat Immunol. 2012;13(4):369-378.
7. Estupiñán HY, Berglof A, Zain R, et al. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol. 2021;9:630942.
centers for the clinical trials included in this analysis. This analysis was sponsored by BeiGene Co, Ltd. Medical writing and editorial assistance were provided by Jenna M. Gaska, PhD, of Nucleus Global, an Inizio Company, and supported by BeiGene.
Funding
This work was supported by funding from BeiGene USA, Inc. Data analyses were performed by biostatisticians at BeiGene USA, Inc, and BeiGene (Beijing) China.
Data-sharing statement
BeiGene voluntarily shares anonymous data on completed studies responsibly and provides qualified scientific and medical researchers access to anonymous data and supporting clinical trial documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations. In addition, data can only be shared when it is feasible to do so without compromising the privacy of study participants. Qualified researchers may submit data requests/research proposals for BeiGene review and consideration through BeiGene’s Clinical Trial Webpage at https://www.beigene.com/our-science-and- medicines/our-clinical-trials/.
8. Thandra KC, Barsouk A, Saginala K, et al. Epidemiology of non- Hodgkin’s lymphoma. Med Sci (Basel). 2021;9(1):5.
9. Hester LL, Park SI, Wood WA, et al. Cause-specific mortality among Medicare beneficiaries with newly diagnosed non- Hodgkin lymphoma subtypes. Cancer. 2019;125(7):1101-1112.
10. Coutre SE, Byrd JC, Hillmen P, et al. Long-term safety of single- agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019;3(12):1799-1807.
11. Gordon MJ, Jones JE, George B, et al. Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: focus on hypertension and cardiovascular toxicity. Cancer. 2023;129(14):2192-2200.
12. Brown JR, Moslehi J, O’Brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102(10):1796-1805.
13. Fleming MR, Xiao L, Jackson KD, et al. Vascular impact of cancer therapies: the case of BTK (Bruton tyrosine kinase) inhibitors. Circ Res. 2021;128(12):1973-1987.
14. McMullen JR, Boey EJ, Ooi JY, et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124(25):3829-3830.
15. Barr PM, Brown JR, Hillmen P, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017;129(19):2612-2615.
Haematologica | 109 July 2024
2283